Search

Your search keyword '"Lee, Jacob"' showing total 297 results

Search Constraints

Start Over You searched for: Author "Lee, Jacob" Remove constraint Author: "Lee, Jacob" Database Unpaywall Remove constraint Database: Unpaywall
297 results on '"Lee, Jacob"'

Search Results

4. Effectiveness of COVID-19 XBB.1.5 monovalent mRNA vaccine in Korea: interim analysis

10. Nucleocapsid (NP) with NP-Specific IgG Induce M2b Macrophages (HLA-DRHighCCR7-CD86 ), Which Contribute to the Hyperproduction of IL-10 and L-6, in Severe and Critical COVID‐19 Patients

11. Effectiveness of Bivalent mRNA Booster Vaccine Against COVID-19 in Korea

12. Impact of Infection Prevention Programs on Catheter-Associated Urinary Tract Infections Analyzed in Multicenter Study

14. Updated Clinical Practice Guidelines for the Diagnosis and Management of long COVID

15. Manejo de residuos sólidos peligrosos durante el derrame de hidrocarburo en Ventanilla

18. KAT6A mutations in Arboleda-Tham syndrome drive epigenetic regulation of posterior HOXC cluster

19. Immunogenicity and safety of SARS-CoV-2 recombinant protein nanoparticle vaccine GBP510 adjuvanted with AS03: interim results of a randomised, active-controlled, observer-blinded, phase 3 trial

23. KAT6A mutations in Arboleda-Tham syndrome drive epigenetic regulation of posterior HOXC cluster

29. Abstract LB339: PARP inhibition reprograms CD8 T cells, enhancing their function and generation of prolonged memory, leading to greater anti-tumor immune response

30. Immunogenicity and safety of SARS-CoV-2 recombinant protein nanoparticle vaccine GBP510 adjuvanted with AS03: randomised, active-controlled, observer-blinded, phase 3 trial

33. Community-Acquired Pneumococcal Pneumonia in Highly Vaccinated Population: Analysis by Serotypes, Vaccination Status, and Underlying Medical Conditions

38. 1066 Pharmacologic inhibition of DGKα activates T cells and enhances anti-tumor immunity

43. COVID-19 vaccine type-dependent differences in immunogenicity and inflammatory response: BNT162b2 and ChAdOx1 nCoV-19

44. Safety and immunogenicity of a SARS-CoV-2 recombinant protein nanoparticle vaccine (GBP510) adjuvanted with AS03: A randomised, placebo-controlled, observer-blinded phase 1/2 trial

Catalog

Books, media, physical & digital resources